1. CELlid’s 5 Billion Won Lawsuit: What Happened?

On September 18, 2025, CELlid announced a ‘Trademark Use Prohibition Injunction Appeal’. Filed by GreenGenius Co., Ltd., this lawsuit aims to prohibit CELlid from using its “for.baker” trademark for its e-commerce business. The claimed amount is a substantial 5 billion won, representing 9.77% of CELlid’s assets. The outcome of this lawsuit could significantly impact the company’s future.

2. CELlid’s Fundamentals: Positive vs. Negative Factors

  • Positive Factors: Completion of Phase 3 clinical trials for COVID-19 vaccine, stable revenue from e-commerce, growth potential of CMO/CDMO business, capital secured through rights offering.
  • Negative Factors: Continuous operating losses, high R&D expenses, uncertainties in new drug development, and this trademark lawsuit.

3. Impact of the Lawsuit on CELlid’s Stock Price

  • Direct Impact: “for.baker” accounts for 99.9% of CELlid’s total revenue. A ban on trademark use will inevitably lead to a sharp decline in sales.
  • Financial Burden: A 5 billion won payment would exacerbate CELlid’s financial difficulties and necessitate additional fundraising.
  • Stock Price Decline: Negative investor sentiment is likely to put downward pressure on the stock price, increasing volatility.

4. Investor Action Plan: What Should You Do Now?

Investors should closely monitor the outcome of the lawsuit and the company’s response strategy. The potential for short-term stock price decline necessitates cautious investment decisions. Maintaining a wait-and-see approach until uncertainties are resolved is advisable. Continuously monitor further disclosures and news releases.